Session » RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1240

An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1203

Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1236

Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials

9:00AM-11:00AM: Abstract Number: 1214

Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1232

Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)

9:00AM-11:00AM: Abstract Number: 1238

Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials

9:00AM-11:00AM: Abstract Number: 1206

Associations of Vascular and Bone Status in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 1228

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials

9:00AM-11:00AM: Abstract Number: 1229

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1202

Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1223

Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History

9:00AM-11:00AM: Abstract Number: 1230

Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1213

Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1201

Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials

9:00AM-11:00AM: Abstract Number: 1217

Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells

9:00AM-11:00AM: Abstract Number: 1221

Evaluation of Methotrexate Efficacy and Exploration of Metabolites Associated with Disease Activity in Collagen-induced Arthritis Mouse Model

9:00AM-11:00AM: Abstract Number: 1216

Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1218

Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate

9:00AM-11:00AM: Abstract Number: 1215

Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

9:00AM-11:00AM: Abstract Number: 1224

Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab

9:00AM-11:00AM: Abstract Number: 1207

Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1220

Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1222

Iron Management in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1234

Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab

9:00AM-11:00AM: Abstract Number: 1226

Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK

9:00AM-11:00AM: Abstract Number: 1237

Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials

9:00AM-11:00AM: Abstract Number: 1241

Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries

9:00AM-11:00AM: Abstract Number: 1210

Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study

9:00AM-11:00AM: Abstract Number: 1239

Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1231

Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years

9:00AM-11:00AM: Abstract Number: 1235

Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND

9:00AM-11:00AM: Abstract Number: 1219

Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial

9:00AM-11:00AM: Abstract Number: 1227

Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 1211

Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1205

Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy

9:00AM-11:00AM: Abstract Number: 1225

Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy

9:00AM-11:00AM: Abstract Number: 1209

The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w

9:00AM-11:00AM: Abstract Number: 1204

Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA

9:00AM-11:00AM: Abstract Number: 1233

Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA

9:00AM-11:00AM: Abstract Number: 1208

Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial

9:00AM-11:00AM: Abstract Number: 1212

Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].